Search clinical trials for: Humanized anti-CD20 monoclonal antibody

Total 100109 results

Genentech, Inc.
Roche Pharma AG

Terminated

A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM) (FILM)

Rheumatoid Arthritis
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Genentech, Inc.
Roche Pharma AG

Terminated

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE) (STAGE)

Rheumatoid Arthritis

United States
Beijing Doing Biomedical Co., Ltd.

Not yet recruiting

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Lymphoma | Leukemia

China
National Institute of Allergy and Infectious Diseases...
Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric...

Completed

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Kidney Transplant | Kidney Transplant Recipient | Graft Function/Survival | de Novo HLA Antibodies Development

United States
Genentech, Inc.
Roche Pharma AG

Terminated

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) (SCRIPT)

Rheumatoid Arthritis

United States, Belgium, Canada, Hungary, Argentina, Germany, Spain, Brazil, Poland, Israel, Mexico, Japan, France, Peru, Switzerland, Sweden, Italy, Australia, New Zealand, Panama, Czechia, Netherlands, Slovakia, Slovenia, Taiwan
Christian Buske
Roche Pharma AG; University of Ulm; Zentrum für Klinische Studien Ulm; X-act Cologne... and other collaborators

Active, not recruiting

Obinutuzumab in Marginal Zone Lymphoma

Marginal Zone Lymphoma

Germany
Gilead Sciences

Completed

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
Fujian Medical University

Recruiting

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma (A-02)

Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

China
Novartis Pharmaceuticals

Recruiting

WOE of Anti-CD20 Therapies

Multiple Sclerosis

United States
Amsterdam UMC, location VUmc
Stichting Treatmeds

Recruiting

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS (Noisy Rebels)

Nervous System Diseases | Multiple Sclerosis | Demyelinating Autoimmune Diseases, CNS | Autoimmune Diseases of the Nervous System | Demyelinating Diseases | Multiple Sclerosis, Relapsing-Remitting

Netherlands
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Terminated

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Southwest Hospital, China

Unknown

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
Claudio Gobbi
Merck AG Switzerland

Active, not recruiting

Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

Multiple Sclerosis

Switzerland
Takeda

Terminated

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis (VELVET)

Rheumatoid Arthritis

United States, Argentina, Canada, Czech Republic, Germany, Hungary, Italy, Mexico, Poland, Spain, United Kingdom
Memorial Sloan Kettering Cancer Center
Adaptive Biotechnologies

Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Miltenyi Biomedicine GmbH

Active, not recruiting

MB-CART20.1 Lymphoma

Non-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

Germany
The University of Hong Kong

Completed

Optimizing HBV Management During Anti-CD20 Antibodies

Hepatitis B | Liver Dysfunction | Immune Suppression

Hong Kong
National Institute of Allergy and Infectious Diseases...
Autoimmunity Centers of Excellence

Completed

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

Sjogren's Syndrome

United States
Novartis Pharmaceuticals

Terminated

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG)

Leukaemia, Lymphocytic, Chronic

Belgium, Netherlands, United States, Argentina, Czechia, Denmark, France, Greece, Israel, Russian Federation, Sweden, Korea, Republic of, Australia, Brazil, Canada, Italy, Spain, Turkey, Hungary, Finland, Poland, Ukraine, Puerto Rico, Indi... and more
The First Affiliated Hospital of Soochow University

Enrolling by invitation

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

China
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive
Pfizer
Trubion Pharmaceuticals/Emergent BioSolutions Inc.

Terminated

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Germany, Hungary, Serbia, Belgium, France, Netherlands, Mexico, Canada, Romania
HaEmek Medical Center, Israel

Active, not recruiting

HBV Reactivation in Anti CD20 Treatment

Hepatitis B

Israel
National Institute of Allergy and Infectious Diseases...
Autoimmunity Centers of Excellence

Completed

Anti-CD20 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Applied Molecular Evolution

Completed

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Mario Negri Institute for Pharmacological Research

Recruiting

Autoreactive B Cells in Membranous Nephropathy (PEPTIDE)

Membranous Nephropathy

Italy
Henri Mondor University Hospital

Completed

Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Primary Immune Thrombocytopenia
McGill University Health Centre/Research Institute...
McGill University

Terminated

Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)

Complex Regional Pain Syndromes

Canada
University Hospital, Rouen

Completed

Effect of Anti CD20 in Pemphigus Desease

Pemphigus

France
Altor BioScience

Terminated

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

United States
Shenzhen Second People's Hospital

Unknown

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

China
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
Abramson Cancer Center at Penn Medicine
Xencor, Inc.

Active, not recruiting

XmAb20717 in Advanced Biliary Tract Cancers

Biliary Tract Cancer

United States
BioMérieux

Completed

Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa

Malaria | Dengue | Chikungunya

Burkina Faso, Côte D'Ivoire
Mayo Clinic

Completed

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

COVID-19 | Convalescent Plasma | Immunosuppressed Host | Anti-CD20 Therapy

United States
Loewenstein Hospital
Meir Medical Center

Unknown

LMWH-VTE Prophylaxis for Survivors of Acute Ischemic Stroke- Assessment of Standard Dosing Regimen

Stroke

Israel
United Nations Office on Drugs and Crime (UNODC)
Polytechnique University of the Philippines; Anti-Drug Abuse Councils, LGUs...

Enrolling by invitation

Assessing the Feasibility of Providing a Family Skills Intervention "Strong Families" for Families in the Philippines. (SF_RCT_POPHL)

Family Relationship | Parenting Skills

Philippines
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
Chinese SLE Treatment And Research Group

Recruiting

Anti-CD20 Antibodies for Treatment of SLE-PAH

Systemic Lupus Erythematosus | Pulmonary Arterial Hypertension

China
Shanghai Jiaolian Drug Research and Development...
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Cho Pharma Inc.

Recruiting

A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

Taiwan, United States
GlaxoSmithKline

Completed

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

Arthritis, Rheumatoid

Russian Federation, Australia, Belgium, Spain, United States, New Zealand, Italy, Poland, France
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
University Hospital, Brest
Ministry of Health, France

Completed

Tolerance and Efficacy of Rituximab in Sjogren's Disease (TEARS)

Sjogren's Disease

France
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China

Search clinical trials for: Humanized anti-CD20 monoclonal antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations